Is lurasidone (Latuda) 40 mg, after being stopped for 7 days, completely cleared from my system?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lurasidone Clearance After 7 Days

After 7 days off Latuda 40 mg, lurasidone is NOT completely cleared from your system. While the majority of the drug has been eliminated, measurable levels and potential effects may persist beyond this timeframe.

Pharmacokinetic Timeline

Based on the FDA drug label, lurasidone has a mean elimination half-life of 18 hours 1. Using standard pharmacokinetic principles:

  • After 3-4 half-lives (54-72 hours): approximately 87.5-94% eliminated
  • After 5 half-lives (90 hours/3.75 days): approximately 97% eliminated
  • After 7 days (168 hours): roughly 99% eliminated under normal circumstances

However, complete clearance requires 5-7 half-lives, meaning trace amounts may persist up to 5-6 days in most individuals 1.

Important Caveats That Extend Clearance

Individual Variation

The FDA label reports a 7% coefficient of variation in half-life, meaning some individuals may have elimination times ranging from 16-20 hours 1. This translates to complete clearance taking anywhere from 4-7 days in different people.

Factors That Prolong Elimination

Obesity significantly delays clearance. Research demonstrates that obese individuals (BMI >40) have a lurasidone half-life of approximately 53 hours compared to 31 hours in normal-weight individuals 2. In obese patients, complete elimination could take 10-14 days.

Metabolic factors matter:

  • Lurasidone is metabolized via CYP3A4 1
  • Concurrent medications affecting this enzyme can alter clearance
  • Liver or kidney impairment extends elimination time
  • Genetic variations in CYP3A4 activity affect individual clearance rates 3

Active Metabolites

Lurasidone produces two active metabolites (ID-14283 and ID-14326) that may persist longer than the parent drug 1. While their clinical significance is limited (the parent drug provides primary activity), they contribute to overall system presence.

Clinical Implications

At 7 days post-discontinuation:

  • Most individuals: >99% cleared, minimal to no detectable drug effect
  • Obese individuals: potentially 50-75% cleared, possible residual effects
  • Those with metabolic variations: variable clearance

Withdrawal symptoms from antipsychotics typically emerge within 2-3 half-lives and resolve within 7-14 days 4, 5. By day 7, acute withdrawal symptoms should be resolving if they occurred.

For drug interactions: If you're starting a medication that interacts with lurasidone or CYP3A4, waiting 7 days provides adequate clearance for most normal-weight individuals. Obese individuals should wait 2-3 weeks 2.

Bottom Line

While 7 days represents substantial elimination (>99% in most people), complete clearance technically requires 5-7 half-lives (approximately 4-6 days for average individuals, potentially 10-14 days for obese individuals). The clinical significance of trace amounts remaining after 7 days is minimal for most purposes, but individual factors—particularly obesity and metabolic variations—can significantly extend this timeline.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.